Search research articles
Contact Us
Filters
Showing results (691-700 of 703) with videos related to
Page
of 71
Sort By:
Breast Cancer Research and Treatment
|
August 17, 2023
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes
Lauren Lenz, Chris Neff, Cara Solimeno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2022
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)
Erica L Mayer, Christian Fesl, Dominik Hlauschek, et al.
JCO Oncology Advances
|
May 18, 2026
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial
Moriah Forster, Fengmin Zhao, Sarah Bell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)
E L Mayer, D Hlauschek, M Gnant, et al.
Science Translational Medicine
|
August 11, 2017
Genomic profiling of ER<sup>+</sup> breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance
Jennifer M Giltnane, Katherine E Hutchinson, Thomas P Stricker, et al.
ESMO Open
|
June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)
M J Naughton, D M Zahrieh, M Gnant, et al.
Breast Cancer Research and Treatment
|
March 27, 2025
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer
Eileen Shinn, David Zahrieh, Angela DeMichele, et al.
Cell Reports. Medicine
|
April 16, 2024
Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
Joline Ingels, Laurenz De Cock, Dieter Stevens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2021
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Michael Gnant, Amylou C Dueck, Sophie Frantal, et al.
The Lancet. Oncology
|
January 18, 2021
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
Erica L Mayer, Amylou C Dueck, Miguel Martin, et al.
Page
of 71
Search research articles
Search
Showing results (691-700 of 703) with videos related to
Sort By:
Page
of 71
Breast Cancer Research and Treatment
|
August 17, 2023
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes
Lauren Lenz, Chris Neff, Cara Solimeno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2022
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)
Erica L Mayer, Christian Fesl, Dominik Hlauschek, et al.
JCO Oncology Advances
|
May 18, 2026
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial
Moriah Forster, Fengmin Zhao, Sarah Bell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)
E L Mayer, D Hlauschek, M Gnant, et al.
Science Translational Medicine
|
August 11, 2017
Genomic profiling of ER<sup>+</sup> breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance
Jennifer M Giltnane, Katherine E Hutchinson, Thomas P Stricker, et al.
ESMO Open
|
June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)
M J Naughton, D M Zahrieh, M Gnant, et al.
Breast Cancer Research and Treatment
|
March 27, 2025
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer
Eileen Shinn, David Zahrieh, Angela DeMichele, et al.
Cell Reports. Medicine
|
April 16, 2024
Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
Joline Ingels, Laurenz De Cock, Dieter Stevens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2021
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Michael Gnant, Amylou C Dueck, Sophie Frantal, et al.
The Lancet. Oncology
|
January 18, 2021
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
Erica L Mayer, Amylou C Dueck, Miguel Martin, et al.
Page
of 71